ImmuCell to Announce Unaudited Financial Results for Second Quarter of 2020
August 06 2020 - 08:00AM
ImmuCell Corporation (Nasdaq: ICCC)
(“ImmuCell” or the “Company”), a growing animal health company that
develops, manufactures and markets scientifically-proven and
practical products that improve the health and productivity of
dairy and beef calves, will report unaudited financial results for
the quarter ended June 30, 2020 after the market closes on
Wednesday, August 12, 2020.
The Company has scheduled a conference call the next morning,
Thursday, August 13, 2020, at 9:00 AM ET to review the results.
Interested parties can access the conference call scheduled by
the Company to review these results by dialing (844) 855-9502 (toll
free) or (412) 317-5499 (international) at 9:00 AM ET on Thursday,
August 13, 2020. A teleconference replay of the call will be
available for seven days at (877) 344-7529 (toll free) or (412)
317-0088 (international), utilizing confirmation #10145671.
The Company expects to file its Quarterly Report on Form 10-Q on
Wednesday, August 12, 2020. Investors are encouraged to review the
Company’s updated Corporate Presentation slide deck that provides
an overview of the Company’s business which will be posted under
the “Investors” tab of the Company’s website at www.immucell.com
after the market closes on Wednesday, August 12, 2020, or by
request to the Company.
About ImmuCell: ImmuCell Corporation's
(Nasdaq: ICCC) purpose is to create
scientifically-proven and practical products that improve the
health and productivity of dairy and beef calves. ImmuCell
manufactures and markets First Defense®, providing
Immediate Immunity™ to newborn dairy and beef
calves, and is in the late stages of developing
Re-Tain™, a novel treatment for subclinical
mastitis without a milk discard requirement that provides an
alternative to traditional antibiotics. Press releases and
other information about the Company are available at:
http://www.immucell.com.
Contact: |
Michael F. Brigham,
President and CEO |
|
ImmuCell
Corporation |
|
(207) 878-2770 |
|
|
|
Joe Diaz, Robert
Blum and Joe Dorame |
|
Lytham Partners,
LLC |
|
(602) 889-9700 |
|
iccc@lythampartners.com |
Cautionary Note Regarding Forward-Looking Statements
(Safe Harbor Statement):This Press Release contains
“forward-looking statements” within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. Such statements include, but are not limited
to, any statements relating to: our plans and strategies for our
business; projections of future financial or operational
performance; the timing and outcome of pending or anticipated
applications for regulatory approvals; factors that may affect the
dairy and beef industries and future demand for our products; the
extent, nature and duration of the COVID-19 pandemic and its
consequences, and their direct and indirect impacts on the
Company’s production activities, operating results and financial
condition and on the customers and markets the Company serves; the
scope and timing of ongoing and future product development work and
commercialization of our products; future costs of product
development efforts; the estimated prevalence rate of subclinical
mastitis and producers’ level of interest in treating subclinical
mastitis given the current economic and market conditions; the
expected efficacy of new products; estimates about the market size
for our products; future market share of and revenue generated by
current products and products still in development; our ability to
increase production output and reduce costs of goods sold
associated with our new product, Tri-Shield
First Defense®; the future adequacy of our own
manufacturing facilities or those of third parties with which we
have contractual relationships to meet demand for our products on a
timely basis; the anticipated costs of (or time to complete)
planned expansions of our manufacturing facilities and the adequacy
of our funds available for these projects; the continuing
availability to us on reasonable terms of third-party providers of
critical products or services; the robustness of our manufacturing
processes and related technical issues; estimates about our
production capacity, efficiency and yield; the future adequacy of
our working capital and the availability and cost of third-party
financing; the forgiveness of our repayment obligations with
respect to the loan we received under the CARES Act; future
regulatory requirements relating to our products; future expense
ratios and margins; future compliance with bank debt covenants;
costs associated with sustaining compliance with current Good
Manufacturing Practice (cGMP) regulations in our current operations
and attaining such compliance for the facility to produce the Nisin
Drug Substance; implementation of international trade tariffs that
could reduce the export of dairy products, which could in turn
weaken the price received by our customers for their products; our
effectiveness in competing against competitors within both our
existing and our anticipated product markets; the
cost-effectiveness of additional sales and marketing expenditures
and resources; anticipated changes in our manufacturing
capabilities and efficiencies; the value of our net deferred tax
assets; projections about depreciation expense and its impact on
income for book and tax return purposes; anticipated market
conditions; and any other statements that are not historical facts.
Forward-looking statements can be identified by the use of words
such as “expects”, “may”, “anticipates”, “aims”, “intends”,
“would”, “could”, “should”, “will”, “plans”, “believes”,
“estimates”, “targets”, “projects”, “forecasts”, “seeks” and
similar words and expressions. In addition, there can be no
assurance that future developments affecting us will be those that
we anticipate. Such statements involve risks and uncertainties,
including, but not limited to, those risks and uncertainties
relating to difficulties or delays in development, testing,
regulatory approval, production and marketing of our products
(including the First Defense® product line and
Re-Tain™), competition within our anticipated
product markets, customer acceptance of our new and existing
products, product performance, alignment between our manufacturing
resources and product demand, our reliance upon third parties for
financial support, products and services, changes in laws and
regulations, decision making and delays by regulatory authorities,
currency values and fluctuations and other risks detailed from time
to time in filings we make with the SEC, including our Quarterly
Reports on Form 10-Q, our Annual Reports on Form 10-K and our
Current Reports on Form 8-K. Such statements involve risks and
uncertainties and are based on our current expectations, but actual
results may differ materially due to various factors, including the
risk factors summarized above.
ImmuCell (NASDAQ:ICCC)
Historical Stock Chart
From Feb 2024 to Mar 2024
ImmuCell (NASDAQ:ICCC)
Historical Stock Chart
From Mar 2023 to Mar 2024